FDA Approves AstraZeneca's Farxiga to Treat Chronic Kidney Disease

 The U.S. Food and Drug Administration on Friday said it approved AstraZeneca PLC's Farxiga as a treatment for chronic kidney disease.

The FDA said Farxiga, or dapagliflozin, oral tablets were approved "to reduce the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression."

The FDA also said, "Farxiga was originally approved in 2014 to improve glycemic control in adults with type 2 diabetes in addition to diet and exercise."

https://www.marketscreener.com/quote/stock/ASTRAZENECA-PLC-4000930/news/FDA-Approves-AstraZeneca-s-Farxiga-to-Treat-Chronic-Kidney-Disease-33125519/